[ad_1]
Eli Lilly & Co. said its antibody-based drug prevents Covid-19 among many residents and staff in nursing homes and assisted living centers, findings which indicate vaccines supplement the drug so as inoculations increase.
The drug, called bamlanivimab, reduced the risk of staff and residents falling ill with Covid-19 by about 57% compared to a placebo eight weeks after receiving doses, Lilly said Thursday. The effect was most pronounced among residents, the company said, an 80% reduction in the risk of Covid-19.
The results signal the potential of a new preventative weapon that could increase the nascent Covid-19 vaccination effort to stem the pandemic.
Lilly said he would ask U.S. health regulators to expand the permitted use of the drug to include protection of people in long-term care facilities where someone has recently been diagnosed with Covid-19.
The partial results were from a final stage, or phase 3, study conducted in partnership with the National Institutes of Health. Lilly disclosed the data in a press release and said she plans to publish the full results in a peer-reviewed medical journal.
Source link
